Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 358

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1

De Clercq, Erik·1998·Antiviral Research
DOI 10.1016/s0166-3542(98)00025-4
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0166-3542(98)00025-4

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 98 references

Research works printed but not linked: 48

  1. Baba, 1991, Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives, Mol. Pharmacol., 39, 805
  2. Balzarini, 1997, The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with other antiretroviral drugs, Antiviral Chem. Chemother., 8, 197, 10.1177/095632029700800303 · doi:10.1177/095632029700800303
  3. Balzarini, 1992, [2′,5′-Bis-O-(tert-butyldimethylsilyl)]-3′-spiro-5′′-[4′′-amino-1′′,2′′-oxathiole-2′′,2′′-dioxide) (TSAO) derivatives of purine and pyrimidine nucleosides as potent and selective inhibitors of human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 36, 1073, 10.1128/AAC.36.5.1073 · doi:10.1128/aac.36.5.1073
  4. Balzarini, 1993, Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus, Virology, 196, 576, 10.1006/viro.1993.1513 · doi:10.1006/viro.1993.1513
  5. Balzarini, 1994, Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720, J. Virol., 68, 7986, 10.1128/JVI.68.12.7986-7992.1994 · doi:10.1128/jvi.68.12.7986-7992.1994
  6. Balzarini, 1995, Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives against different human immunodeficiency virus type 1 mutant strains, Antimicrob. Agents Chemother., 39, 998, 10.1128/AAC.39.4.998 · doi:10.1128/aac.39.4.998
  7. Balzarini, 1995, Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives), Proc. Natl. Acad. Sci. USA, 92, 5470, 10.1073/pnas.92.12.5470 · doi:10.1073/pnas.92.12.5470
  8. Balzarini, 1996, Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2′,3′-dideoxy-3′-thiacytidine, Mol. Pharmacol., 49, 882
  9. Balzarini, 1996, Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication, Mol. Pharmacol., 50, 394
  10. Balzarini, 1996, Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors, Proc. Natl. Acad. Sci. USA, 93, 13152, 10.1073/pnas.93.23.13152 · doi:10.1073/pnas.93.23.13152
  11. Balzarini, 1997, Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine, J. Infect. Dis., 176, 1392, 10.1086/517329 · doi:10.1086/517329
  12. Balzarini, 1998, Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-dihydroquinoxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2′,3′-dideoxy-3′-thiacytidine (lamivudine), Biochem. Pharmacol., 55, 617, 10.1016/S0006-2952(97)00506-6 · doi:10.1016/s0006-2952(97)00506-6
  13. Barth, 1996, Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation, Antiviral Chem. Chemother., 7, 300, 10.1177/095632029600700603 · doi:10.1177/095632029600700603
  14. Boyer, 1998, A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer, Antimicrob. Agents Chemother., 42, 447, 10.1128/AAC.42.2.447 · doi:10.1128/aac.42.2.447
  15. Buckheit, 1995, Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase, Virology, 210, 186, 10.1006/viro.1995.1330 · doi:10.1006/viro.1995.1330
  16. Buckheit, 1997, Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates, Antimicrob. Agents Chemother., 41, 831, 10.1128/AAC.41.4.831 · doi:10.1128/aac.41.4.831
  17. Byrnes, 1994, Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 38, 1404, 10.1128/AAC.38.6.1404 · doi:10.1128/aac.38.6.1404
  18. Chimirri, 1997, Structural features and anti-human immunodeficiency virus (HIV) activity of the isomers of 1-(2′,6′-difluorophenyl)-1H,3H-thiazolo[3,4-a]benzimidazole, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor, Antiviral Chem. Chemother., 8, 363, 10.1177/095632029700800409 · doi:10.1177/095632029700800409
  19. Chong, 1994, Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3′-azido-3′-deoxythymidine or 2′,3′-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro, Antimicrob. Agents Chemother., 38, 288, 10.1128/AAC.38.2.288 · doi:10.1128/aac.38.2.288
  20. Craib, 1997, Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection, J. Infect. Dis., 176, 798, 10.1086/517305 · doi:10.1086/517305
  21. Davey, 1996, Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients, Antimicrob. Agents Chemother., 40, 1657, 10.1128/AAC.40.7.1657 · doi:10.1128/aac.40.7.1657
  22. Debyser, 1992, Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase, Mol. Pharmacol., 41, 963
  23. De Clercq, 1996, Non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of human immunodeficiency virus type 1 (HIV-1) infections: strategies to overcome drug resistance development, Med. Res. Rev., 16, 125, 10.1002/(SICI)1098-1128(199603)16:2<125::AID-MED1>3.0.CO;2-2 · doi:10.1002/(sici)1098-1128(199603)16:2<125::aid-med1>3.0.co;2-2
  24. De Clercq, 1997, In search of a selective antiviral chemotherapy, Clin. Microbiol. Rev., 10, 674, 10.1128/CMR.10.4.674 · doi:10.1128/cmr.10.4.674
  25. De Wit, 1992, Pharmacokinetics of R 82913 in AIDS patients: a phase I dose-finding study of oral administration compared with intravenous infusion, Antimicrob. Agents Chemother., 36, 2661, 10.1128/AAC.36.12.2661 · doi:10.1128/aac.36.12.2661
  26. Dueweke, 1993, A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors, Proc. Natl. Acad. Sci. USA, 90, 4713, 10.1073/pnas.90.10.4713 · doi:10.1073/pnas.90.10.4713
  27. Esnouf, 1997, Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives, Biochem. Biophys. Res. Commun., 234, 458, 10.1006/bbrc.1997.6552 · doi:10.1006/bbrc.1997.6552
  28. Goldman, 1992, L-696,229 specifically inhibits human immunodeficiency virus type 1 reverse transcriptase and possesses antiviral activity in vitro, Antimicrob. Agents Chemother., 36, 1019, 10.1128/AAC.36.5.1019 · doi:10.1128/aac.36.5.1019
  29. Ijichi, 1996, Anti-HIV-1 activity of thiadiazole derivatives: a structure–activity relationship, reverse transcriptase inhibition, and lipophilicity, Antiviral Res., 31, 87, 10.1016/0166-3542(96)00950-3 · doi:10.1016/0166-3542(96)00950-3
  30. Kleim, 1994, Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase, Virology, 200, 696, 10.1006/viro.1994.1233 · doi:10.1006/viro.1994.1233
  31. Kleim, 1997, In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitory HBY 097, Virology, 231, 112, 10.1006/viro.1997.8513 · doi:10.1006/viro.1997.8513
  32. Mayers, D., Riddler, S., Bach, M., Stein, D.F., Havlir, M.D., Kahn, J., Ruiz, N., Labriola, D.F. and the DMP 266 Clinical Development Team, 1997. Durable clinical anti-HIV-1 activity and tolerability for DMP 266 in combination with indinavir (IDV) at 24 weeks. 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, 30 September 1997, abstract I-175.
  33. Mertens, 1993, Selective non-nucleoside HIV-1 reverse transcriptase inhibitors. New 2,3-dihydrothiazolo[2,3-a]isoindol-5(9H)-ones and related compounds with anti-HIV-1 activity, J. Med. Chem., 36, 2526, 10.1021/jm00069a011 · doi:10.1021/jm00069a011
  34. Miyasaka, 1989, A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine, J. Med. Chem., 32, 2507, 10.1021/jm00132a002 · doi:10.1021/jm00132a002
  35. Moxham, 1997, Preliminary efficacy, pharmacokinetics and safety of repeated multiple doses of MKC-442 in HIV-infected volunteers. Abstracts of the Tenth International Conference on Antiviral Research, Atlanta, GA, 6–11 April 1997, Antiviral Res., 34, A44, 10.1016/S0166-3542(97)83151-8 · doi:10.1016/s0166-3542(97)83151-8
  36. Okamoto, 1996, Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells, Antiviral Res., 31, 69, 10.1016/0166-3542(96)00946-1 · doi:10.1016/0166-3542(96)00946-1
  37. Pagano, 1995, In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-α, J. Infect. Dis., 171, 61, 10.1093/infdis/171.1.61 · doi:10.1093/infdis/171.1.61
  38. Pelemans, 1997, Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1, J. Virol., 71, 8195, 10.1128/JVI.71.11.8195-8203.1997 · doi:10.1128/jvi.71.11.8195-8203.1997
  39. Pialoux, 1991, Pharmacokinetics of R 82913 in patients with AIDS or AIDS-related complex, Lancet, 338, 140, 10.1016/0140-6736(91)90135-C · doi:10.1016/0140-6736(91)90135-c
  40. Romero, 1993, Bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure–activity relationships of novel substituted indole analogues and the identification of 1-[(5-methanesulfonamido-1H-indol-2-yl)carbonyl]-4-[3-[(1-methylethyl)amino]pyridinyl]piperazine monomethanesulfonate (U-90152S), a second-generation clinical candidate, J. Med. Chem., 36, 1505, 10.1021/jm00062a027 · doi:10.1021/jm00062a027
  41. Rübsamen-Waigmann, 1997, Second-generation non-nucleoside reverse transcriptase inhibitor HBY 097 and HIV-1 viral load, Lancet, 349, 1517, 10.1016/S0140-6736(97)24021-3 · doi:10.1016/s0140-6736(97)24021-3
  42. Sahai, 1996, Risks and synergies from drug interactions, AIDS, 10, S21
  43. Schooley, 1996, Phase 1 study of combination therapy with L-697,661 and zidovudine, J. Acquired Immune Defic. Syndr. Hum. Retrovirol., 12, 363, 10.1097/00042560-199608010-00006 · doi:10.1097/00042560-199608010-00006
  44. Skowron, G., Leoung, G., Dusek, A., Anderson, R., Grosso, R., Jacobs, M., Lamson, M., Kerr, B., Beebe, S., 1998. dNN study: stavudine (d4T), nelfinavir (NFV), and nevirapine (NVP): preliminary safety, activity, and pharmacokinetic (PK) interactions. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1–5 February 1998, abstract 350.
  45. Staszewski, 1996, Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients, Antiviral Ther., 1, 42
  46. Staszewski, 1996, Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients, AIDS, 10, F1, 10.1097/00002030-199605000-00001 · doi:10.1097/00002030-199605000-00001
  47. Winslow, 1996, Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266, AIDS, 10, 1205, 10.1097/00002030-199609000-00005 · doi:10.1097/00002030-199609000-00005
  48. Yuasa, 1993, Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442, Mol. Pharmacol., 44, 895

Cited by

See all 358

Metadata

Authors
De Clercq, E.
Venue
Antiviral Research
Publisher
Elsevier BV
Published
1998-06
Volume
38
Issue
3
Pages
153-179
ISSN
0166-3542 (ISSN-L)
DOI
10.1016/s0166-3542(98)00025-4
OpenAlex
W2117784959
Cited by
358
References
98
FWCI
19.59
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1. https://app.cochat.ai/papers/10.1016/s0166-3542(98)00025-4
The paper
De Clercq, E. (1998). The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection1Presented at the Eleventh International Conference on Antiviral Research, San Diego, CA, 5–10 April 1998.1. Antiviral Research. https://doi.org/10.1016/s0166-3542(98)00025-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.